These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 26789111)

  • 21. Normalization of the vasculature for treatment of cancer and other diseases.
    Goel S; Duda DG; Xu L; Munn LL; Boucher Y; Fukumura D; Jain RK
    Physiol Rev; 2011 Jul; 91(3):1071-121. PubMed ID: 21742796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.
    Jain RK; Tong RT; Munn LL
    Cancer Res; 2007 Mar; 67(6):2729-35. PubMed ID: 17363594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
    Heist RS; Duda DG; Sahani DV; Ancukiewicz M; Fidias P; Sequist LV; Temel JS; Shaw AT; Pennell NA; Neal JW; Gandhi L; Lynch TJ; Engelman JA; Jain RK
    Proc Natl Acad Sci U S A; 2015 Feb; 112(5):1547-52. PubMed ID: 25605928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.
    Limaverde-Sousa G; Sternberg C; Ferreira CG
    Cancer Treat Rev; 2014 May; 40(4):548-57. PubMed ID: 24360358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.
    Brauer MJ; Zhuang G; Schmidt M; Yao J; Wu X; Kaminker JS; Jurinka SS; Kolumam G; Chung AS; Jubb A; Modrusan Z; Ozawa T; James CD; Phillips H; Haley B; Tam RN; Clermont AC; Cheng JH; Yang SX; Swain SM; Chen D; Scherer SJ; Koeppen H; Yeh RF; Yue P; Stephan JP; Hegde P; Ferrara N; Singh M; Bais C
    Clin Cancer Res; 2013 Jul; 19(13):3681-92. PubMed ID: 23685835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
    Hicklin DJ; Ellis LM
    J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-angiogenic therapy against gastrointestinal tract cancers.
    Iwasaki J; Nihira S
    Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
    Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
    Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
    Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy.
    Smith NR; Baker D; Farren M; Pommier A; Swann R; Wang X; Mistry S; McDaid K; Kendrew J; Womack C; Wedge SR; Barry ST
    Clin Cancer Res; 2013 Dec; 19(24):6943-56. PubMed ID: 24030704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy.
    Greenberg JI; Cheresh DA
    Expert Opin Biol Ther; 2009 Nov; 9(11):1347-56. PubMed ID: 19761418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiangiogenic therapy: Markers of response, "normalization" and resistance.
    El Alaoui-Lasmaili K; Faivre B
    Crit Rev Oncol Hematol; 2018 Aug; 128():118-129. PubMed ID: 29958627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
    Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
    Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
    Dickson PV; Hamner JB; Sims TL; Fraga CH; Ng CY; Rajasekeran S; Hagedorn NL; McCarville MB; Stewart CF; Davidoff AM
    Clin Cancer Res; 2007 Jul; 13(13):3942-50. PubMed ID: 17606728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor angiogenesis and vascular normalization: alternative therapeutic targets.
    Viallard C; Larrivée B
    Angiogenesis; 2017 Nov; 20(4):409-426. PubMed ID: 28660302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.
    Niu G; Chen X
    Curr Drug Targets; 2010 Aug; 11(8):1000-17. PubMed ID: 20426765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
    Vangestel C; Van de Wiele C; Van Damme N; Staelens S; Pauwels P; Reutelingsperger CP; Peeters M
    J Nucl Med; 2011 Nov; 52(11):1786-94. PubMed ID: 22045708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.
    Goldberg RM; Hurwitz HI; Fuchs CS
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):1-10; quiz 11. PubMed ID: 16555433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.